46th European Association for the Study of the Liver (EASL), 30 March-3 April 2011, Berlin, Germany

The development of compounds that directly target hepatitis C virus (direct acting antivirals or DAA’s), used with and without pegylated interferon (PEG-IFN) and ribavirin is moving rapidly and with a burgeoning pipeline.

The following report is an edited summary of a rapid summary from Jules Levin whose website posted numerous studies from this meeting.

Abstracts from the oral and poster sessions are available online at the following links:

A limited number of web casts are due to be posted online but were not yet available when HTB went to press.

Links to other websites are current at date of posting but not maintained.